Dr. Ali Al-Ghamrawy, Chairman of the EDA, held a meeting with representatives of East Pharma, headed by Mr. Philippe Haas, the company’s Global Executive Chairman and CEO, to discuss ways to strengthen investment in Egypt’s pharmaceutical sector, explore plans for expanding local manufacturing, facilitate the transfer of modern technologies, and develop production and research capabilities. These efforts aim to support Egypt’s drive to localize pharmaceutical manufacturing and strengthen pharmaceutical products security.
Dr. Al-Ghamrawy emphasized the EDA’s commitment to strengthening cooperation with global pharmaceutical companies and fostering a regulatory environment that supports strategic investments and industrial expansion. This includes deepening local manufacturing, transferring and localizing advanced pharmaceutical technologies, and developing production capabilities, while ensuring compliance with approved regulatory standards and safeguarding the quality, safety, and efficacy of pharmaceutical products.
Mr. Philippe Haas outlined the company’s investment priorities in the Egyptian market and its expansion plans for the coming years. He highlighted the company’s interest in strengthening its presence in Egypt, supporting local manufacturing, and developing industrial and technological capabilities to help meet the needs of the Egyptian market and create opportunities for growth and expansion in the pharmaceutical sector.
The meeting reviewed the company’s current investments and future plans, including the expansion of production lines, with a focus on developing complex pharmaceutical products and strengthening local research and development capabilities. The two sides discussed opportunities for transferring manufacturing technologies and leveraging international industrial expertise to advance the Egyptian pharmaceutical industry and enhance its competitiveness.
The meeting further addressed mechanisms for expanding the availability of pharmaceutical products in the Egyptian market and developing manufacturing capabilities in accordance with applicable regulatory frameworks and requirements. Discussions also covered facilitating access to priority pharmaceutical products based on market needs, while respecting the regulations governing intellectual property rights and patents.
This meeting comes as part of the EDA’s strategy to strengthen partnerships with global pharmaceutical companies, attract strategic investments, support the localization of advanced pharmaceutical industries, and facilitate the transfer of modern technologies. These efforts aim to enhance the competitiveness of Egypt’s pharmaceutical industry, expand its production and export capabilities, and ensure the availability of pharmaceutical products needed to meet the needs of Egyptian patients.